Specifications tableSubject areaChemistryMore specific subject areaComputational chemistryType of dataTable, figureHow data was acquiredLigand based molecular docking using FlexX and Maestro softwareData formatRaw and analyzedExperimental factorsPhytoconstituents structures downloaded from PubChem were subjected to Avogadro software for energy minimization.Experimental featuresMinimized ligands structures were docked with seven selected protein structure using FlexX software.Data source locationDepartment of bioinformatics, Dr. D. Y. Patil Biotechnology & Bioinformatics Institute Tathawade, PuneData accessibilityData is only with this articleRelated research articleK. H. Min, J. Yoo, H. Park, Computer-Aided Identification of Ligands for GPCR Anti-Obesity Targets, Curr Top Med Chem. 9 (2009) 539--553 [@bib1].**Value of the data**•Obesity declared as a disease by WHO and is the main cause of other many metabolic disorders which lead to mortality.•Literature explains multiple mechanisms involved in energy uptake and energy consumption, the control of which can help in maintaining energy balance and thus keeping obesity at large.•This article provides all dataset of protein structures to explore potential targets for obesity.•In-silico exploration of targets is the first step in drug design to understand the underlying mechanism of action of the identified drug molecule.•Many herbal medicines and food supplements are found to be beneficial in reducing body weight, although mode of action and identification of marker phytoconstituents is still not explored.•Docking of phytoconstituents to seven identified targets for obesity can pave a way towards identification of novel anti-obesity drug.

1. Data {#sec1}
=======

This dataset contains docking analysis of phytoconstituents of *Hibiscus rosa-sinensis* on different targets of obesity. Different secondary metabolites present in *Hibiscus rosa-sinensis* were selected. Chemical structures of selected phytoconstituents were taken from database and were subjected to energy minimization. Seven receptor structures were selected as potential targets of obesity [@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8]. Protein structures available in database were downloaded from RCSB protein databank. [Table 1](#tbl1){ref-type="table"} gives details of the selected receptors. Two receptors model were prepared using I-TASSER server online. [Table 2](#tbl2){ref-type="table"} summarizes FASTA sequence of Ghrelin and MCH1 receptor subjected to model preparation. Phytoconstituents were docked on the above targets to understand binding interactions. [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"}, [Table 8](#tbl8){ref-type="table"}, [Table 9](#tbl9){ref-type="table"} summarizes the dock score, bond distance and interacting amino acid residue of all phytoconstituents on seven different targets. [Fig. 1](#fig1){ref-type="fig"}-14 gives docked images of phytoconstituents with lowest dock score and standard drug orlistat with seven receptor proteins.Table 1Table summarizing details of targets selected.Table 1TargetPDB IDDescriptionResolutionR value freeR value workPancreatic Lipase1LPBThe 2.46 Å resolution structure of the pancreatic lipase colipase complex inhibited by a c11 alkyl phosphonate2.46 Å0.2850.183Fat And Obesity Protein3LFMCrystal structure of the fat mass and obesity associated (FTO) protein reveals basis for its substrate specificity2.5 Å0.2850.239Cannabinoid Receptor5TGZCrystal structure analysis of w35f/h207w mutant of human clic12.3 Å0.3060.240Leptin1AX8Human obesity protein, leptin2.4 Å0.2830.185SCH1 Protein4XWXCrystal structure of the PTB domain of SHC1.87 Å0.1910.168Table 2Uniprot ID and FASTA sequence of ghrelin and MCH1 receptor.Table 2TargetUniProt IDFASTA sequenceGhrelin receptor[Q9UBU3](uniprotkb:Q9UBU3){#intref0015}MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPEDGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADKMCH 1 receptor[Q99705](uniprotkb:Q99705){#intref0020}MSVGAMKKGVGRAVGLGGGSGCQATEEDPLPNCGACAPGQGGRRWRLPQPAWVEGSSARLWEQATGTGWMDLEASLLPTGPNASNTSDGPDNLTSAGSPPRTGSISYINIIMPSVFGTICLLGIIGNSTVIFAVVKKSKLHWCNNVPDIFIINLSVVDLLFLLGMPFMIHQLMGNGVWHFGETMCTLITAMDANSQFTSTYILTAMAIDRYLATVHPISSTKFRKPSVATLVICLLWALSFISITPVWLYARLIPFPGGAVGCGIRLPNPDTDLYWFTLYQFFLAFALPFVVITAAYVRILQRMTSSVAPASQRSIRLRTKRVTRTAIAICLVFFVCWAPYYVLQLTQLSISRPTLTFVYLYNAAISLGYANSCLNPFVYIVLCETFRKRLVLSVKPAAQGQLRAVSNAQTADEERTESKGTTable 3Summary of docking analysis with pancreatic lipase (PDB ID 1LPB).Table 3Sr. NoPosenameScoreInteracting ResiduesBond TypeBond Distance1Niacin−27.2868SER 333HB2.01ARG 265Pi-Pi Stacking5.21HB1.79Salt bridge3.08LYS 239Salt bridge2.732Quercetin 3, 7 diglucoside−21.223LYS 239HB1.93ASP 247HB1.93ASP 257HB1.71TRY 267HB1.98THR 271HB2.70LYS 268HB1.48Pi cation5.10ASP 249HB2.123Ascorbic acid−20.6315SER 333HB2.32ASP 247HB2.06ARG 265HB2.18ASP 257HB2.17ASP 249HB1.794Quercetin 3, 3′ diglucoside−20.3198SER 3332HB2.12,2.31ASP 247HB2.34ASP 331HB1.84ARG 265HB2.20ASP 257HB2.66TYR 267HB2.2.3ASN 88HB2.525Quercetin 3,4′ diglucoside−18.4448ASP 3312HB2.18, 2,07ARG 265HB1.90SER 333HB2.29PHE 335Pi Pi stacking5.46ASN 88HB2.6168 nonynoic acid−17.7764LYS 239HB2.04Salt Bridge3.91ARG 265HB1.9379 Decynoic acid−17.4676ARG 2652HB2.11, 1.85LYS 239HB1.94Salt bridge4.678Cyanidine 3, 5 diglucoside−15.6327ARG 265PI Pi stacking4.92ASP 247HB1.91ASP 257HB1.89ASP 249HB2.11Salt Bridge4.60GLU 253HB2,29SER 333HB2.39LYS 268HB2.29ASP 272HB2.089Riboflavin−15.3182ASP 249HB1.36SER 333HB1.60GLU 253HB2.16LYS 268HB1.7110Thiamine−14.7694ASP 249HB1.97Salt Bridge4.85ARG 265Pi Pi stacking4.94LYS 268Pi cation2.86ASP 247HB2.0711Beta rosasterol−9.4736LYS 239HB2.16ARG 265HB2.1612Cyanidin 3-sophoroside-5-glucoside−8.2017ASP 2493HB1.46, 2.02, 1.91ASP 272HB2.02GLU 2532HB1.82, 1.8113Methyl non-8-ynoate−7.2264LYS 239HB2.05ARG 265HB1.9414Methyl Dec-9-ynoate−5.9149LYS 239HB2.05ARG 265HB1.9415Methyl (E)-11-methoxy-9-oxononadec-10-enoate−4.9341SER 333HB2.14ARG 265HB2.15TRY 267HB2.14LYS 268HB2.1216Methyl malvalate−3.6439LYS 239HB2.05ARG 265HB1.9417Methyl 8-oxooctadec-9-ynoate−2.8512SER 333HB2.10LYS 239HB1.89ARG 265HB2.0218Methyl Sterculate−1.1816ARG 265HB1.98LYS 239HB2.0619Campesterol1.5909GLU 253HB2.2820Stigmasterol2.651ASP 249HB1.90GLU 253HB2.1221Beta sitosterol3.2084No interaction**22Orlistat0.1075ASP 249HB1.68SER 333HB1.94TYR 267HB2.23Ar HB1.91**[^1]Table 4Summary of docking analysis with fat and obesity protein (PDB ID 3LFM).Table 4Sr. No.LigandScoreInteracting ResiduesBond TypeBond Distance1Riboflavin−27.3248ARG 96HB1.62SER 229HB2.07GLU 234HB2.01Ar HB2.352Niacin−21.5279ARG 322HB1.93GLU 234HB1.84ARG 96Pi-Pi Stacking4.263Thiamine−19.313TRY 108Pi-Pi Stacking4.78HIP 231Pi-Pi Stacking3.68Pi-Pi Stacking5.45Pi Cation4.42Pi Cation3.78SER 229HB1.38TYR 106HB2.004Ascorbic acid−16.8546ASP 233HB1.99ARG 322HB2.45ARG 96HB1.99GLU 234HB1.905Cyanidine 3, 5 diglucoside−14.6454ARG 322Pi Cation5.23HB1.52TRY 106HB2.08HB1.81HIP 232HB1.82GLU 234HB2.25HIP 231Pi-Pi Stacking4.81Pi-Pi Stacking5.43VAL 94HB1.536Quercetin 3,4′ diglucoside−12.747VAL 94HB2.35GLU 234HB2.00HIP 232HB1.57HB1.91GLN 306HB2.18HIP 231Pi Cation6.3878 nonynoic acid−12.149ASN 205HB1.96ARG 322HB2.05Salt bridge3.78ARG 96HB1.7889 Decynoic acid−11.8069ARG 322HB1.97GLU 234HB1.979Quercetin 3,3′ diglucoside−11.2637TYR 108Pi-Pi Stacking4.55ARG 96HB2.66VAL 94HB1.79ALA 227HB2.24GLU 234HB1.6210Quercetin 3,7 diglucoside−7.7494GLU 234HB2.04HB2.16TYR 108Pi-Pi Stacking4.94TYR 106HB2.29ARG 322HB1.71HIP 231Pi-Pi Stacking3.98HIP 232HB2.0611Methyl 8-oxooctadec-9-ynoate−6.5642HIP 232HB1.93ARG 96HB1.5212Methyl Dec-9-ynoate−4.8041ARG 96HB2.1513Methyl non-8-ynoate−4.4543ARG 96HB2.1514(9) Methyl (E)-11-methoxy-9-oxononadec-10-enoate−2.4721ARG 96HB2.1515Beta rosasterol−1.029VAL 94HB1.7816Methyl Sterculate0.5157ARG 96HB1.8417Methyl malvalate0.7329ARG 96HB1.8818Beta sitosterol1.2521ALA 227HB2.219Campesterol1.447ALA 227HB2.2120**Orlistat−7.2466ARG 322HB2.20GLU 234HB2.04HB1.66HIP 232HB2.17**[^2]Table 5Summary of docking analysis with cannabinoid receptor (PDB ID 3TGZ).Table 5Sr. No.LigandScoreInteracting ResiduesBond TypeBond Distance1Niacin−14.7132MET 103HB1.84ASP 104HB2.072Thiamine−13.5476PHE 102Pi-Pi Stacking4.92SER 383HB1.81SER 123HB1.693Ascorbic acid−11.9942ASP 163HB2.30TRP 356HB1.70CYS 386HB1.86SER 199HB2.44ALA 162HB2.124Riboflavin−9.4202PHE 170Pi-Pi Stacking5.43MET 103HB1.96SER 383HB2.0658 nonynoic acid−4.3902ASP 104HB1.8469 Decynoic acid−3.8828ASP 104HB1.95MET 103HB1.837Methyl 8-oxooctadec-9-ynoate−3.0906ASN 389HB2.66TRP 356HB1.868Methyl non-8-ynoate−2.5398TRP 356HB1.959Methyl Dec-9-ynoate−2.4934TRP 356HB1.9510(9) Methyl (E)-11-methoxy-9-oxononadec-10-enoate−2.1673TRP 356HB1.9511Quercetin 3,3′ diglucoside−1.505SER 383HB2.61TRP 356HB2.51SER 390HB1.5012Methyl malvalate−0.5677No Interaction13Methyl Sterculate−0.2554ASN 389HB2.50TRP 356HB1.8514Quercetin 3,4′ diglucoside−0.201PHE 174Pi-Pi Stacking5.44ASP 104HB2.1415Campesterol3.5794No Interaction16Beta rosasterol6.619817Beta sitosterol6.619818**Orlistat−1.7877MET 103HB1.82ASP 104HB2.09SER 383HB1.65**[^3]Table 6Summary of docking analysis with leptin (PDB ID 1AX8).Table 6Sr. No.LigandDock ScoreInteracting residuesBond TypeBond distance1Riboflavin−18.4869GLN 134HB2.22HB1.91GLN 130HB2.12HB1.72ASP 40HB2.08HB1.58Ar HB2.21ILE 21HB1.802Cyanidine 3, 5 diglucoside−13.4683ASP 40HB1.49HB2.40HB1.75HB1.68GLN 130HB1.87HB1.83GLN 134HB2.41ILE 21HB1.86HB1.533Thiamine−11.3807GLN 134HB2.21ASP 40HB2.15ILE 42HB1.844Ascorbic acid−11.1364GLY 44HB1.94GLN 134HB1.98HB2.205Quercetin 3,4′ diglucoside−10.9657GLY 44HB2.57HB2.27ASP 135HB2.15GLN 130HB1.90ASP 40HB2.05LEU 39HB1.84HB1.926Quercetin 3,3′ diglucoside−10.3108ASP 40HB2.29SER 127HB1.607Quercetin 3,7 diglucoside−10.2723PHE 41Pi-Pi Stacking5.04GLN 130HB1.97ASP 40HB2.07GLY 131HB1.56GLY 44HB1.64ASP 135HB1.568Niacin−9.3776ASP 40HB1.849Beta rosasterol−6.3064GLY 44HB1.8210Cyanidin 3-sophoroside-5-glucoside−5.2426GLN 134HB1.84ASP 135HB2.07HB2.54LEU 39HB1.84GLN 130HB1.99PHE 41HB1.84HB1.9111Campesterol−3.5982No interaction12Stigmasterol−2.8915ASP 135HB2.22GLY 44HB2.40138 nonynoic acid0.1127OHE 41HB2.0114Beta sitosterol0.4685ASP 135HB1.97GLY 44HB2.48159 Decynoic acid1.1976ASP 40HB1.88PHE 41HB1.8616Methyl non-8-ynoate2.0473PHE 41HB1.8917Methyl Dec-9-ynoate2.8153PHE 41HB1.9518Methyl 8-oxooctadec-9-ynoate5.4298PHE 41HB1.8719(9) Methyl (E)-11-methoxy-9-oxononadec-10-enoate6.5759PHE 41HB1.8320Methyl Sterculate6.9274PHE 41HB1.8721Methyl malvalate8.0895PHE 41HB1.8722**Orlistat8.3009ASP 40HB1.71GLU 134HB1.80GLY 44HB1.99**[^4]Table 7Summary of docking analysis with SCH1 protein (PDB ID 4XWX).Table 7Sr. No.LigandDock scoreInteracting residuesBond typeBond angle1Riboflavin−13.553ARG 74Pi cation5.25Pi Pi stacking4.72ILE 150HB1.68ALA 153HB1.84SER 151HB1.95HB2.192Niacin−11.0861PHE 198Pi-Pi Stacking4.933Ascorbic acid−8.3129ALA 153HB2.20HB1.90SER 151HB1.58HB1.884Thiamine−8.2065ALA 153HB1.53PHE 198Pi-Pi Stacking4.09ILE 150HB1.735Quercetin 3,3′ diglucoside−6.2583GLY 195HB1.94ALA 153HB1.58ILE 191HB2.10HB2.49PHE 198Pi -- Pi Stacking5.06SER 151HB2.24ILE 150HB1.61HB1.756Cyanidine 3, 5′ diglucoside−4.9771GLU 199Salt Bridge2.92PHE 198Pi Pi Stacking4.73ALA 153HB2.15HB2.17SER 151HB1.84WATERHB2.43ILE 150HB1.81HB1.777Campesterol−4.5453ALA 153HB1.928Beta sitosterol−1.7076ILE 191HB1.9599 Decynoic acid−1.6636ARG 74Salt Bridge4.96108 nonynoic acid−1.5286ARG 74Salt Bridge4.9611Stigmasterol−1.0801No interaction12Quercetin 3,4′ diglucoside0.3325GLY 155HB2.43WATERHB2.17ALA 153HB1.88HB2.07HB2.33SER 151HB2.02PHE 198Pi Pi Stacking5.32GLY 195HB2.2613Beta rosasterol0.3474No interaction14Methyl non-8-ynoate0.47715Methyl Dec-9-ynoate1.045216Quercetin 3,7 diglucoside2.2611WATERHB1.14HB0.61HB2.50ILE 150HB1.76HB1.66SER 151HB1.76ARG 74Pi Cation3.8417Methyl 8-oxooctadec-9-ynoate3.4243No Interaction18Methyl malvalate5.857519Methyl Sterculate6.880820(9) Methyl (E)-11-methoxy-9-oxononadec-10-enoate7.744321Cyanidin 3-sophoroside-5-glucoside8.522222**Orlistat10.3508ALA 153HB1.86**[^5]Table 8Summary of docking analysis with ghrelin.Table 8Sr. No.LigandDock scoreInteracting residuesBond typeBond angle1Niacin−11.1374ALA 53HB2.36ASN 76HB1.852Ascorbic acid−7.2393PRO 49HB2.15HB1.86GLN 36HB1.77ALA 77HB2.183Riboflavin−7.0131ALA 77HB2.40GLN 36HB1.68HB1.59ASN 76HB1.624Thiamine−4.7344GLN 36HB1.77ALA 77HB2.13HIE 32Pi-Pi Stacking5.3358 nonynoic acid1.9189ASN 76HB1.8469 Decynoic acid2.7981ALA 77HB2.137Methyl non-8-ynoate2.9037No interaction8Methyl Dec-9-ynoate4.00359Campesterol6.911510Methyl 8-oxooctadec-9-ynoate8.7284GLU 36HB2.20ASN 76HB1.9211Methyl malvalate11.8293ALA 77HB2.1812Methyl Sterculate12.0917No interaction13Beta sitosterol12.201514(9) Methyl (E)-11-methoxy-9-oxononadec-10-enoate13.291515**Orlistat15.8166ASN 76HB1.65ALA 77HB2.20**[^6]Table 9Summary of docking analysis with MCH1.Table 9Sr. No.LigandDock scoreInteracting residuesBond typeBond angle1Quercetin 3,3′ diglucoside−13.7266ASP 91HB1.96HB1.74GLY 80HB1.76GLY 18HB2.00SER 57HB1.732Riboflavin−12.9742GLY 18HB2.19HB2.10SER 87HB2.36SER 57HB1.553Thiamine−9.527LEU 16HB1.82HB1.90GLU 54Salt Bridge4.99HB1.904Quercetin 3,7 diglucoside−8.7967VAL 3HB2.02LEU 76HB1.63ACE 0HB2.10GLU 80HB2.24ASP 91HB2.355Cyanidine 3, 5′ diglucoside−8.3388LEU 76HB1.68ACE 0HB1.63HB1.51VAL 3HB2.31ASP 91HB1.55HB1.58SER 87HB1.76GLY 18HB2.316Ascorbic acid−7.7733SER 57HB2.19HB1.80GLU 54HB1.76HB1.657Cyanidin 3-sophoroside-5-glucoside−5.7144LEU 76HB1.70ASP 91HB1.62HB1.65GLY 18HB1.73ACE 0HB1.92HB1.728Quercetin 3,4′ diglucoside−5.236GLY 15HB2.09VAL 14HB2.35SER 57HB1.74SER 87HB2.20ASP 91HB1.56HB1.429Niacin−5.127VAL 3HB1.8410Campesterol−0.843GLU 54HB2.1611Stigmasterol−0.787GLU 54HB1.9312Beta sitosterol1.849GLU 54HB2.0013Beta rosasterol2.848No interaction148 nonynoic acid3.749VAL 3HB1.84159 Decynoic acid4.120VAL 3HB1.8416Methyl Dec-9-ynoate5.030VAL 3HB1.8917Methyl non-8-ynoate5.193VAL 3HB1.8918(9) Methyl (E)-11-methoxy-9-oxononadec-10-enoate8.373TRP 61HB1.7519Methyl 8-oxooctadec-9-ynoate8.384SER 2HB2.0320VAL 3HB1.8921Methyl malvalate11.003VAL 3HB1.8922Methyl Sterculate11.447VAL 3HB1.8923**Orlistat11.712Glu 54HB2.09**[^7]Fig. 11LPB interaction with Niacin.Fig. 1

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Ligand preparation {#sec2.1}
-----------------------

Twenty two phytoconstituents present in *Hibiscus rosa-sinensis* were selected. Structures of all phytoconstituents were downloaded from PubChem database. Orlistat (PubChem CID 3034010) only available synthetic drug was used as reference standard.

2.2. Energy minimization {#sec2.2}
------------------------

All structures were subjected to energy minimization using Avogadro software where universal force field (UFF) and first order steepest descent algorithm were used. This gave energetically stable conformations for the structures. Avogadro is free open source molecular builder software used for molecular modeling. It calculates the lowest energy conformation from the bond lengths and bond angles with smallest steric energy. Energy minimization helps in attaining structure conformation with lower delta G values which is considered close to biological system.

2.3. Retrieval of protein structure and preparation {#sec2.3}
---------------------------------------------------

Seven targets which play important role in maintaining energy balance of body and thus address obesity were selected. Protein structures of ligands were downloaded from the RCSB Protein Data Bank, database for 3D structures of large biological molecules, including proteins and nucleic acids. Downloaded protein structures were prepared X ray crystal structure of PDB ID 1LPB, 3LFM, 3TGZ, 1AX8, 4XWX for pancreatic lipase [@bib2], FTO protein [@bib3], cannabinoid receptor [@bib4], hormones leptin [@bib5] and protein SCH1 [@bib6] respectively were selected. Data summarized in [Table 1](#tbl1){ref-type="table"}.

X- Ray crystal structure for Ghrelin [@bib7] and MCH1 [@bib8] receptor is not available in PDB databank so model protein structure was created using I-TASSER server online. FASTA sequence was taken from Uniprot ID of protein and submitted for model preparation. [Table 2](#tbl2){ref-type="table"} summarizes FASTA sequence of Ghrelin and MCH1. Model was evaluated for C-score, TM score and RMSD. Model with C-score between −5 and 2, TM score greater than 0.5 were selected. Finalized model were validated on PROSA, Saves v5.0, Ramachandran plot and ProQ and then were used as receptors.

2.4. Molecular docking studies {#sec2.4}
------------------------------

Molecular docking techniques dock small molecules into the protein binding site. In order to understand how these ligands bind to the enzyme, docking analysis were performed using FlexX software. The receptor ligand interactions were done using Maestro software. Interacting amino acid residue, bond type and bond distance were noted.

Data summarized in [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"}, [Table 8](#tbl8){ref-type="table"}, [Table 9](#tbl9){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"}, [Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}, [Fig. 10](#fig10){ref-type="fig"}, [Fig. 11](#fig11){ref-type="fig"}, [Fig. 12](#fig12){ref-type="fig"}, [Fig. 13](#fig13){ref-type="fig"}, [Fig. 14](#fig14){ref-type="fig"}.Fig. 21LPB interaction with Orlistat.Fig. 2Fig. 33LFM interaction with Riboflavin.Fig. 3Fig. 43LFM interaction with Orlistat.Fig. 4Fig. 53TGZ interaction with Niacin.Fig. 5Fig. 63TGZ interaction with Orlistat.Fig. 6Fig. 71AX8 interaction with Riboflavin.Fig. 7Fig. 81AX8 interaction with Orlistat.Fig. 8Fig. 94XWX interaction with Riboflavin.Fig. 9Fig. 104XWX interaction with Orlistat.Fig. 10Fig. 11Ghrelin interaction with Niacin.Fig. 11Fig. 12Ghrelin interaction with Orlistat.Fig. 12Fig. 13MCH1 interaction with Riboflavin.Fig. 13Fig. 14MCH1 interaction with Orlistat.Fig. 14
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[^1]: Orlistat, as only standard drug used in market is used as standard reference for docking studies. Hence the docking result of orlistat in all tables is bold for ease of comparison.

[^2]: Orlistat, as only standard drug used in market is used as standard reference for docking studies. Hence the docking result of orlistat in all tables is bold for ease of comparison.

[^3]: Orlistat, as only standard drug used in market is used as standard reference for docking studies. Hence the docking result of orlistat in all tables is bold for ease of comparison.

[^4]: Orlistat, as only standard drug used in market is used as standard reference for docking studies. Hence the docking result of orlistat in all tables is bold for ease of comparison.

[^5]: Orlistat, as only standard drug used in market is used as standard reference for docking studies. Hence the docking result of orlistat in all tables is bold for ease of comparison.

[^6]: Orlistat, as only standard drug used in market is used as standard reference for docking studies. Hence the docking result of orlistat in all tables is bold for ease of comparison.

[^7]: Orlistat, as only standard drug used in market is used as standard reference for docking studies. Hence the docking result of orlistat in all tables is bold for ease of comparison.
